Drugs / Hyperpolarized Xe129
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT06339593 | Jan 2024 → Jan 2028 expected | cystic fibrosis | Children's Hospital Medical Center, Cincinnati | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Hyperpolarized Xe129 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06339593 ↗ |
| Modality | Diagnostic / imaging agent | “will be used as a diagnostic test here” NCT06339593 ↗ |
| Route | Inhaled | “Hyperpolarized Xe gas is an FDA-approved, inhaled contrast agent for lung ventilation MRI” NCT06339593 ↗ |